Posts Tagged ‘nasdaq’

Skyworks Solutions Inc. (SWKS) has above-average trading day on above-market growth

Tuesday, June 7th, 2011

Skyworks Solutions Inc. (Nasdaq: SWKS) shares rose 8.3% to $25.20 Tuesday, after the wireless semiconductor company affirmed its upbeat third-quarter forecast. Volume for the stock 10.8 million shares, more than double its daily average.

The Woburn, Mass.-based company is affirming its outlook for above-market growth, excluding its recently announced acquisitions. In April 2011, Skyworks guided to approximately $345 million in revenue with non-GAAP diluted earnings per share of $0.46 for the current quarter.

Further, during the earnings conference call, the Company indicated it was on a path to approach a $1.5-billion-revenue run rate with $2.00 in annualized non-GAAP diluted earnings per share in the September quarter. This growth outlook is being driven by the Company’s broad customer base, diversification into new markets and increasing share gains.

In the June 7 press release announcing the projections, Skyworks Chief Financial Officer, Donald Palette declared, “Skyworks’ core business continues to outperform our addressed markets and we believe this will be clearly reflected in our performance and guidance.

“To be clear,” Palette concluded, “our revenue and non-GAAP earnings outlook for both the June and September quarters is before we add the accretive SiGe and Advanced Analogic Technologies acquisitions.”

Skyworks Solutions, Inc. is an innovator of high reliability analog and mixed signal semiconductors. Leveraging core technologies, Skyworks offers diverse standard and custom linear products supporting automotive, broadband, cellular infrastructure, energy management, industrial, medical, military and mobile handset applications.

ADA-ES Inc. (ADES) stock hikes after sale of joint-venture interest

Monday, June 6th, 2011

ADA-ES Inc. (Nasdaq: ADES) stock surged 54.7% to $15.47 Monday afternoon, on word it was selling its Clean Coal Solutions LLC holdings to an affiliate of Goldman Sachs. Volume of 594,000 shares proved nearly six times its normal daily average.

The sale concerns a 15.8% equity interest in Clean Coal, ADA’s 50:50 joint venture with an affiliate of NexGen Resources Corporation, by ADA and NexGen for $60 million to GSFS Investments I Corp., an affiliate of The Goldman Sachs Group, Inc. Closing of the transaction was simultaneous with signing.

Clean Coal’s patented coal technology, CyClean, is a cost-effective coal technology to produce Refined Coal, which reduces emissions of NOx and mercury.

Dr. Michael D. Durham, CEO of ADA-ES said, “We are very pleased to welcome this additional investment by Goldman Sachs. We believe that their continued financial interest in Clean Coal further validates the environmental and financial benefits of this proven emissions control technology.

“As we continue to assess ADA’s liabilities resulting from the arbitration panel’s recent interim award to Norit Americas, Inc. and related indemnity obligations, this cash infusion enhances our balance sheet and our ability to fulfill those obligations.”

ADA-ES is a leader in clean coal technology and the associated specialty chemicals, serving the coal-fueled power plant industry.

OXiGENE Inc. (OXGN) surges on new cancer treatment

Monday, June 6th, 2011

OXiGENE Inc. (Nasdaq: OXGN) shares rose 13.8% to $4.87, after the biotech company on Saturday reported encouraging data on a potential treatment for non-small cell lung cancer. Share volume for the stock tallied 2.3 million shares, already surpassing an all-day high of 1.7 million.

The San Francisco-based company announced Saturday that it presented updated safety and clinical activity data from the FALCON trial, a stratified randomized, controlled Phase 2 study of ZYBRESTAT™ (fosbretabulin tromethamine, or CA4P) in patients with non-small cell lung cancer (NSCLC), at the 2011 Annual Meeting of the American Society of Clinical Oncology (ASCO) in Chicago.

An updated analysis conducted approximately 11 months after the enrollment of the last patient in June 2010 showed that the combination regimen of ZYBRESTAT plus bevacizumab, carboplatin and paclitaxel (ZYBRESTAT Arm) was observed to be well-tolerated with no significant cumulative toxicities when compared with the control arm of the study. In addition, a pre-specified subgroup analysis showed meaningful improvements in median time to progression for patients with poor performance status.

Said Dr. Peter Langecker, CEO of OXiGENE, “With several clinical trials completed in multiple indications, we now have a large body of data showing the excellent combinability potential of ZYBRESTAT.

“In addition,” Langecker continued, “this study provides data in non-small cell lung cancer (NSCLC) suggesting that ZYBRESTAT may benefit patients with more advanced stages of disease…. We believe that designing a development plan based on targeting this subgroup of patients could represent a sensible and achievable clinical strategy and we look forward to discussing further development of ZYBRESTAT with potential pharmaceutical partners.”

OXiGENE is a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases. The Company’s major focus is developing vascular disrupting agents that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment.

Apollo Group Inc. (APOL) benefits from government ruling

Thursday, June 2nd, 2011

Apollo Group Inc. (Nasdaq: APOL) shares rose 10.2% to $46.50, after the U.S. Education Department softened a rule that had threatened some aid to for-profit colleges.

The Department of Education on Thursday rolled out a rule that denies federal aid if programs don’t lead to “gainful employment” in a recognized occupation.

But the final rule would deny assistance as early as 2015, rather than immediately, if three tests over student loan repayment weren’t met.

“If you get three strikes in four years, you’re out,” Education Secretary Arne Duncan said in a statement. The department estimates that 18% of for-profit programs are expected to fail the thresholds at some point, with 5% of them failing to improve and ultimately losing eligibility.

Phoenix-based Apollo Group was one of a number of companies in the sector that jumped on the news.

Apollo Group, Inc. is one of the world’s largest private education providers and has been in the education business for more than 35 years. The Company offers innovative and distinctive educational programs and services both online and on-campus at the undergraduate, master’s and doctoral levels through its subsidiaries: University of Phoenix, Apollo Global, Institute for Professional Development and College for Financial Planning.

The Company’s programs and services are provided in 40 states and the District of Columbia; Puerto Rico; Latin America; and Europe, as well as online throughout the world.

Orexigen Therapeutics Inc. (OREX) stock price balloons for diet pill maker

Wednesday, June 1st, 2011

Orexigen Therapeutics Inc. (Nasdaq: OREX) shares jumped 17.7% to $3.33 Wednesday, after the diet-pill developer said it would make a regulatory announcement about its obesity treatment in two days. Volume for the stock was 8.2 million shares, or more than six times its daily average.

The San Diego-based Orexigen has announced a regulatory update on Friday, June 3, before the markets open. The announcement will be followed by a live webcast and conference call at 8:00 a.m. Eastern time. No one from Orexigen management was immediately available for comment.

The company’s lead product, Contrave®, has completed Phase 3 clinical trials and has received a Complete Response Letter from the FDA for its New Drug Application. The Company is in the process of determining the next steps for Contrave.

The Company’s second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches.